Verona, 5th March 2015: Techorizon, today announced the launch of FeRMI, a unique electronic application which brings the conduct of clinical trial feasibility studies into the 21st Century. At the same time, Techorizon also launched a new technically advanced website.
Clinical research projects are often characterized by delays and cost overruns. A crucial step in mitigating against these risks during planning is a detailed feasibility study. To date, such feasibility studies have been largely paper or email based and data have been time consuming to process and analyze. Furthermore, the knowledge base of prior feasibility studies is typically not integrated with the process, and the database of prior investigator site contacts resides as a separate, distinct entity.
Named after the length scale used in nuclear physics in recognition of the detailed data collected, FeRMI creates an entirely integrated, electronic approach to the conduct of feasibility studies and promotes faster, more effective study planning. Each step of the process is managed electronically, with data collection from sites completed via highly customizable online surveys which include real time error checks. The powerful investigator database module speeds selection of potential sites and tracks previous contacts and historical study performance. A powerful real-time reporting module allows users to track trends emerging from the feasibility study whilst in progress, and ultimately to make better decisions about site selection.
‘FeRMI revolutionizes clinical project planning by allowing our clients to conduct faster, more detailed, more accurate feasibility studies’, noted Silvio Severini, Managing Director of Techorizon. ‘FeRMI adds to our Th-eClinical suite and is entirely unique, the first technology application to provide an end-to-end solution for the conduct of feasibility studies’.
About Techorizon: A quality-driven technology company with ISO9001:2008 certification, Techorizon is headquartered in Verona, Italy with North American offices in Cambridge, MA. Services are delivered through Techorizon’s state-of-the-art technology infrastructure maintained in Verona. All Techorizon products are fully validated to GAMP 5 standards as well as being 21 CFR Part 11 compliant. Launched in 2009 as a separate company, Techorizon had previously provided technology services exclusively to CROMSOURCE, a leading international CRO. Techorizon serves clients of all sizes within the clinical research and wider Healthcare industry.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.